NCT00330616View on ClinicalTrials.gov

Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

323U66 SR

Trial Locations (9)

815-0041

GSK Investigational Site, Fukuoka

961-0021

GSK Investigational Site, Fukushima

861-8002

GSK Investigational Site, Kumamoto

395-0056

GSK Investigational Site, Nagano

399-8695

GSK Investigational Site, Nagano

332-0012

GSK Investigational Site, Saitama

164-0012

GSK Investigational Site, Tokyo

170-0002

GSK Investigational Site, Tokyo

189-0012

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00330616 - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan | Biotech Hunter | Biotech Hunter